Concerned about the decrease in the effectiveness of existing vaccines due to mutations of the corona virus, scientists started clinical testing of the third dose vaccine in the USA to protect against variants in California, England, South Africa and Brazil. Hundreds of volunteers were included in trials in which an updated version of Moderna was tested. .
“WE NEED TO BE ONE STEP AHEAD OF THE VIRUS”
Emory University’s Dr. Nadine Rouphael said, “We need to stay ahead of the virus. We have experienced what it is like to stay behind. We do not yet know whether the protection provided by existing vaccines will provide enough protection against mutations. But we want to realistically defeat Covid-19,” he said.
A LARGE PART OF THE WORLD IS TOO LACK IN VACCINATION
On the other hand, the corona virus is constantly mutating, the world is competing to vaccinate billions of people and destroy the corona virus before more variation emerges. According to Health Ministry data until now in Turkey were vaccinated more than 19 million people and about 7 and a half million of them was the second dose of vaccine. However, most of the rest of the world is far behind this speed.
VACCINE MANUFACTURERS BOTH THE IDEA ON SOUTH AFRICA MUTATION IS A WORRIER
A version that appeared in the UK just months ago and is easier to spread has now become the most common variant in the World. But globally, there is concern that first generation vaccines may offer less protection against a different variant that first appeared in South Africa. All major vaccine manufacturers agreed that an update should be made against the B.1.351 variant.
In this context, Emory University asked people who had Moderna’s original vaccine in the first trials a year ago to help test the updated vaccine. Volunteer Cole Smith said returning was not a difficult decision.
The study, funded by the National Institutes of Health, doesn’t just test Moderna’s experimental variant vaccine as a third-shot immune booster. Researchers at Emory and three other medical centers are also enrolling volunteers who have not yet had any Covid-19 vaccine because the researchers want to examine the effects of both the first version of the vaccine and the updated version together and separately.
On the other hand, the US Food and Drug Administration has given Pfizer and its German partner BioNTech permission to initiate similar tests for their own fine-tuned vaccines.
CORONA VIRUS SPREADED THIS TO THE WORLD